Study: Coope 2026, Pharmaceuticals (Basel)

Back to the Roots: Safety and Tolerability of Standardised Ashwagandha (Withania somnifera) Root Extract in Healthy Adults-A Systematic Review of Biomarkers and Adverse Events

Citation

Coope OC, Willems MET, Levington A, Tallon MJ et al (2026). Pharmaceuticals (Basel). PubMed id 42198398.

Open on PubMed

Cards that cite this study (1)

Each card gives its own wording for who was tested, how and what was found.

  • Ashwagandha: cortisol, mood, skin, hair, heart, kidneys and liver Tier B thin

    B 2,317 healthy adults in 23 randomised trials of standardised, single-ingredient root extract (125 to 600 mg a day, up to 180 days) (n=2317)

    Systematic review of safety and tolerability.

    Liver, kidney, blood, hormone and cardiovascular markers stayed within normal ranges. No serious adverse events attributable to the extract. Mild effects (stomach discomfort, headache, drowsiness) were infrequent and occurred in both treatment and comparison groups. Long-term data beyond 180 days are limited.

    As recorded in this card: Coope OC, Willems MET, Levington A, Tallon MJ et al (2026), Pharmaceuticals (Basel), [review]

    Note: Authors say case reports of harm mostly involved non-standardised or multi-ingredient products. Some authors are affiliated with supplement companies. Healthy adults only, so it says little about people with liver or kidney disease.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.